Nestle Health Science
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nestle Health Science
The company plans an intensive review to determine the path forward for SER-287. A similar deep dive led to the successful revival of its C. difficile drug, SER-109, which it plans to submit for approval.
Mead Johnson pulls challenged claims before National Advertising Division began a review in its SWIFT process, but not before Nestlé Nutrition, which markets Gerber infant formula, submitted its challenge.
Seres and rival Ferring are both hoping to have the first-ever FDA-approved microbiome therapeutic but the US firm has secured a strong commercial partner in Nestlé's Aimmune pharma arm to drive SER-109 over the finishing line.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
- Medical Devices
- OTC, Consumer
- Other Names / Subsidiaries
- Prometheus Laboratories, Inc., Nestle S.A., Aimmune Therapeutics, Inc.